(Adds details on agreement in paragraphs 3-6, background on other AstraZeneca drug in paragraph 7)
Oct 7 (Reuters) - AstraZeneca said on Monday it would pay up to $1.92 billion to CSPC Pharmaceutical Group Ltd
in an exclusive licence agreement to boost the Anglo-Swedish drugmaker's cardiovascular pipeline.
Apart from the aforementioned milestone and royalty payment, Hong Kong-based CSPC will also get an upfront payment of $100 million as part of the deal.
CSPC will develop an early-stage, novel small molecule Lipoprotein (a) disruptor, which could offer benefits to patients with high levels of "bad cholesterol", AstraZeneca said.
Lp(a) is a form of low-density lipoprotein that plays a role in transporting cholesterol in the blood stream.
AstraZeneca said it would have access to CSPC's pre-clinical candidate small molecule - YS2302018 - an oral Lp(a) disruptor, with the aim to develop it as a lipid-lowering therapy.
The asset could help address the major risk factors driving chronic cardiovascular diseases, alone or in combination with other drugs, including AstraZeneca's oral small molecule PCSK9 inhibitor AZD0780, it said.
AZD0780 is being developed as a therapy for patients with dyslipidaemia that cannot be controlled alone by statins, which are drugs that lower blood cholesterol. PSCK9 is a well-known and validated target in lipid metabolism.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)
((Yadarisa.Shabong@thomsonreuters.com; +91 9742735150;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。